{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:52:46Z","timestamp":1791028366632,"version":"4.1.0"},"reference-count":44,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":1800,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2007,2]]},"abstract":"<jats:p>Tegaserod, a selective and partial agonist at the 5\u2010hydroxytryptamine (5\u2010HT [serotonin]) receptor subtype 4 (5\u2010HT<jats:sub>4<\/jats:sub>), is the only United States Food and Drug Administration\u2013approved drug for the treatment of constipation\u2010predominant irritable bowel syndrome (IBS) in women. The drug's stimulation of 5\u2010HT<jats:sub>4<\/jats:sub> receptors on intestinal enterocytes increases peristaltic activity and fluid secretion into the gut lumen, facilitating stool passage. In addition, affinity of tegaserod for 5\u2010HT<jats:sub>4<\/jats:sub> receptors modulates visceral sensitivity, which helps alleviate abdominal pain associated with constipation\u2010predominant IBS. The drug's pharmacokinetic and pharmacodynamic parameters do not differ significantly with age or sex. Tegaserod safely and effectively relieves overall gastrointestinal symptoms and abdominal discomfort and normalizes bowel habits in patients with constipation\u2010predominant IBS. It is associated with few drug interactions. In clinical studies, tegaserod was well tolerated, and its adverse\u2010effect profile was similar to that of placebo. Severe diarrhea, as well as abdominal pain, flatulence, headache, and nausea, were the most commonly reported events. Patients who experience severe diarrhea should discontinue the drug. With the data available, tegaserod remains an option for patients with constipation\u2010predominant IBS.<\/jats:p>","DOI":"10.1592\/phco.27.2.267","type":"journal-article","created":{"date-parts":[[2007,1,25]],"date-time":"2007-01-25T12:41:39Z","timestamp":1169728899000},"page":"267-277","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Tegaserod for Constipation\u2010Predominant Irritable Bowel Syndrome"],"prefix":"10.1002","volume":"27","author":[{"given":"Pramodini B.","family":"Kale\u2010Pradhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila M.","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","volume-title":"Zelnorm (tegaserod) package insert","author":"Novartis Pharmaceutical Corporation.","year":"2004"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0031-6997(25)06783-3","article-title":"VII. International union of pharmacology classification of receptors for 5\u2010hydroxytryptamine (serotonin)","volume":"46","author":"Hoyer D","year":"1994","journal-title":"Pharmacol Rev"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.79.493"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(96)00466-9"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s005350070056"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(24)37929-7"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70203-3"},{"key":"e_1_2_1_9_2","first-page":"A643","article-title":"Dose\u2010dependent modulation of rectal afferent sensitivity by a 5\u2010HT4 receptor agonist [abstr]","volume":"117","author":"Schikowski A","year":"1999","journal-title":"Gastroenterology"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.5.526.33351"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.17.1946"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/S0022-3565(24)36528-0","article-title":"SDZ HTF 919 stimulates canine colonic motility and transit in vivo","volume":"280","author":"Nguyen A","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"e_1_2_1_13_2","first-page":"G3103","article-title":"Investigations on a 5HT4\u2010agonist (SDZ HTF 919) and its main metabolite in conscious dogs: effects on gastrointestinal motility and impaired gastric emptying [abstr]","volume":"114","author":"Fioramonti J","year":"1998","journal-title":"Gastroenterology"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702665"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04785.x"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90050-3"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01103.x"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70251-4"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00973.x"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003251823"},{"issue":"3","key":"e_1_2_1_21_2","first-page":"EXhB5331","article-title":"Pharmacokinetics and safety of SDZ HTF 919, a new promotile drug in healthy subjects and patients with hepatic cirrhosis [abstr]","volume":"59","author":"Appel\u2010Dingemanse S","year":"1998","journal-title":"Digestion"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280000239"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00936.x"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912709922008524"},{"key":"e_1_2_1_25_2","first-page":"1269","article-title":"In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions","volume":"10","author":"Vickers AE","year":"2001","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"e_1_2_1_26_2","first-page":"A64","article-title":"The partial 5HT4 agonist (HTF 919) improves symptoms in constipation\u2010 predominant irritable bowel syndrome (CIBS) [abstr]","volume":"59","author":"Langakaer KJ","year":"1998","journal-title":"Digestion"},{"issue":"3","key":"e_1_2_1_27_2","first-page":"B5324","article-title":"Titration regimen indicates partial 5HT4 agonist HTF 919 improves symptoms of constipation predominant irritable bowel syndrome (CIBS) [abstr]","volume":"59","author":"Hamling J","year":"1998","journal-title":"Digestion"},{"issue":"9","key":"e_1_2_1_28_2","first-page":"A2676","article-title":"The 5HT4 partial agonist, tegaserod, improves abdominal discomfort\/pain and normalizes altered bowel function in irritable bowel syndrome (IBS) [abstr]","volume":"94","author":"Lefkowitz M","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01094.x"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01372.x"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.5.671"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365520310006748"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.070789"},{"key":"e_1_2_1_34_2","first-page":"CD003960","article-title":"Tegaserod for the treatment of irritable bowel syndrome","volume":"1","author":"Evans BW","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(03)00027-1"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.5.2.313"},{"issue":"1","key":"e_1_2_1_37_2","first-page":"21","article-title":"Efficacy and tolerability of tegaserod in constipation dominant irritable bowel syndrome","volume":"14","author":"Shah SH","year":"2004","journal-title":"J Coll Physicians Surg Pak"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02267.x"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.07026.x"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05692.x"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01347.x"},{"key":"e_1_2_1_42_2","unstructured":"U.S. Food and Drug Administration.FDA talk: FDA updates Zelnorm labeling with new risk information.April 28 2004. Available fromhttp:www.fda.govbbstopicsANSWERS2004ANS01285.html. Accessed May 22 2006."},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127000104100909"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122012625"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199907000-00014"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.27.2.267","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.27.2.267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:26:03Z","timestamp":1761053163000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.27.2.267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["10.1592\/phco.27.2.267"],"URL":"https:\/\/doi.org\/10.1592\/phco.27.2.267","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}